Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP2C19 and Voriconazole Therapy

B. Moriyama, A. Owusu Obeng, J. Barbarino, S. R. Penzak, S. A. Henning, S. A. Scott, J. A.G. Agúndez, J. R. Wingard, H. L. McLeod, T. E. Klein, S. J. Cross, K. E. Caudle, T. J. Walsh

Research output: Contribution to journalArticle

86 Scopus citations

Abstract

Voriconazole, a triazole antifungal agent, demonstrates wide interpatient variability in serum concentrations, due in part to variant CYP2C19 alleles. Individuals who are CYP2C19 ultrarapid metabolizers have decreased trough voriconazole concentrations, delaying achievement of target blood concentrations; whereas poor metabolizers have increased trough concentrations and are at increased risk of adverse drug events. We summarize evidence from the literature supporting this association and provide therapeutic recommendations for the use of voriconazole for treatment based on CYP2C19 genotype (updates at https://cpicpgx.org/guidelines/ and www.pharmgkb.org).

Original languageEnglish
Pages (from-to)45-51
Number of pages7
JournalClinical Pharmacology and Therapeutics
Volume102
Issue number1
DOIs
StatePublished - 1 Jul 2017

Fingerprint Dive into the research topics of 'Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP2C19 and Voriconazole Therapy'. Together they form a unique fingerprint.

Cite this